Thank you
@atomikrej for posting the link to the recent webinar transcript and for making we aware of a very interesting bit mentioned here:
MK:
"And we've had a number of new contacts in this regard. Indeed, some companies are thinking about combining their MSC technologies with ours at a project or even at a larger portfolio scale. And this is obviously also driven and underpinned by research results just published this week, but not only providing a mechanistic hypothesis why our technology compares very favorably to some of the other technologies and has indeed some superior features."
When reading this at first, I was wondering how other companies could possibly combine their MSC technologies with ours, especially since we've been told for years that companies already in clinical trials using MSCs from different sources would essentially have to re-do their trials (MSCs = same same, but different), essentially start from scratch, which requires time and cash.
Then
@Artephius made a very interesting comment, "engineered."
Of course, that technologies mentioned by MK is not necessarily the manufacturing process of MSCs, but to genetically engineer MSCs currently sourced from other providers.
If CRISPR-Cas9 sounds too far fetched given where we are at the moment MC and clinical-result-wise, we can already show examples of our MSCs being tested using different engineered approaches:
2016 apceth GmbH & Co KG (private company), unfortunately taken over by Hitachi shortly after concluding their initial research of our cells, and turned into a CDMO, even stripped of their own clinical pipeline in the process.
Shame, but the following had been announced:
"Cynata Partner apceth GmbH & Co Completes Cymerus™ Evaluation"
http://files.cynata.com/258/17.03.31.Cynata-Partner-apceth-GmbH-Co-Completes-Cymerus-Evaluation.pdf"'During the evaluation in our in-house cell culture and genetic modification systems, Cynata's cells demonstrated the necessary characteristics required for use with our technology. We are pleased with the results of the evaluation and continue to work with Cynata to determine the next steps in regard to our collaboration. Its Cymerus platform has huge potential in the area of stem cell product development and its ability to create uniform cells using just one donation from one donor is truly revolutionary', said Dr Christine Günther, Chief Executive Officer at apceth."
Dr Khalid Shah's approach:
"Cynata Engineered MSC Study Review Reveals Promising Results"
https://app.sharelinktechnologies.com/announcement/asx/e98c5a0c23c909750dab7d91e96367d0"The first stage of the study has shown that Cynata’s Cymerus MSCs can be successfully engineered to express the diagnostic and therapeutic proteins using unique expression promoters developed by Dr Shah’s team. Moreover, this expression is stable during continued culture (growth) of the modified MSCs in the lab, and the modified MSCs persist in vivo for a sufficient duration to facilitate a therapeutic effect.
Dr Shah said, “'Cynata’s unique MSCs have so far shown ideal properties required to progress the cells into different disease models. In particular, the modified Cynata cells behave in a very similar fashion to traditional MSCs.”
In early 2021, information had leaked on HC about Kalbe experimenting with our cells for their next gen MSC approach using genetically engineered iPSC:
https://hotcopper.com.au/threads/behind-the-scenes.6067040/?post_id=53276309Company wasn't too happy and refused to make any comments, with sources quoted being removed within a week of the news breaking.
And the most recent example, although not an engineering approach - CYPATCH, for which results have recently been released in DFU. This was initially meant to be tested using cells from a different provider according to early announcements on Govt websites and by CTM CRC, but an initial study comparing our cells as well as cells from various other sources in combination with the patch,iPSC-MSCs were chosen instead:
"Cynata’s Cymerus™ MSCs Effective in Preclinical Model of Diabetic Wounds"
https://files.cynata.com/348/18.05.31.Cynatas-MSCs-Effective-in-Model-of-Diabetic-Wounds.pdfThere is a massive advantage of the above when it comes to sub-licensing our technology: each (genetically) engineered product is separately licensable, even if the same delivery route is being used than for any of our other candidates, i.e. topical, IV or IA.
Lets hear more about these companies KK and MK. If you keep at it this time, the news flow will continue, or as Kevin Costner got told years ago, "If you build it, they will come."
Not sure about you guys that managed to read this far, but it starts to feel like a New Dawn...
(20min delay)